Enorama Pharma AB OMXSTO:ERMA:
Q3 NET SALES -193 (7,481) THOUSAND SEK
Q3 OPERATING PROFIT -12,339 (-4,476) THOUSAND SEK
Enorama Pharma Q3 Operating Loss Widens To SEK 12.3 Mln
Earlier from Enorama Pharma
- Enorama Pharma CEO Daniel Schröder Resigns
- ERMA: Sharp revenue decline and deepening losses in H1 2025 amid US transition and PMTA focus
- ERMA: Losses deepened as Enorama Pharma restructures for US white snus growth and seeks new funding
- ERMA: Strong US snus growth offset by NRT write-down; urgent capital needs remain
- ERMA: Net sales rose sharply and losses narrowed as US pouch sales accelerated
Later from Enorama Pharma
- Bulletin from the extraordinary general meeting in Enorama Pharma AB (publ)
- Enorama Pharma Subsidiary Intends To Appeal FDA's Refuse-To-File Decision
- Enorama Pharma Postpones Its 2025 Year-End Report
- Enorama Pharma Enters Loan Agreement With DS Global
- Enorama Pharma AB (publ) resolves to postpone the planned extraordinary general meeting
Follow Enorama Pharma into a list and get an email when it puts out news.
Follow Enorama Pharma